Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease - Systematic review and meta-analysis

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 352-360

  Ram, Ron ^a,b   Yeshurun, Moshe ^a,b   Vidal, Liat ^a,b   Shpilberg, Ofer ^a,b   Gafter Gvili, Anat ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allogeneic transplantation; Graft versus host disease; Methotrexate; Mycopheolate

Indexed keywords

ALLOGENEIC TRANSPLANTATION; GRAFT-VERSUS-HOST DISEASE; METHOTREXATE; MYCOPHEOLATE;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIDDLE AGED; MUCOSITIS; MYCOPHENOLIC ACID; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84894261460     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.012     Document Type: Article

References (39)

1. Cutler C., Antin J.H. Manifestations and treatment of acute graft-versus-host disease. Thomas' hematopoietic cell transplantation 2009, Wiley-Blackwell, Oxford, UK. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
2. Gratwohl A., Hermans J., Apperley J., Arcese W., Bacigalupo A., Bandini G., et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995, 86(July (2)):813-818.
3. Davies J.K., Lowdell M.W. New advances in acute graft-versus-host disease prophylaxis. Transfus Med 2003, 13(December (6)):387-397.
4. Rezvani A.R., Storb R.F. Prevention of graft-vs.-host disease. Expert Opin Pharmacother 2012, 13(August (12)):1737-1750.
5. Ruutu T., van Biezen A., Hertenstein B., Henseler A., Garderet L., Passweg J., et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012, 47(November (11)):1459-1464.
6. Ram R., Gafter-Gvili A., Yeshurun M., Paul M., Raanani P., Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009, 43(April (8)):643-653.
7. Hahn T., Wall D., Camitta B., Davies S., Dillon H., Gaynon P., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005, 11(November (11)):823-861.
8. Kahl C., Storer B.E., Sandmaier B.M., Mielcarek M., Maris M.B., Blume K.G., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110(October (7)):2744-2748.
9. Collaboration TC. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.
10. Bornhauser M., Schuler U., Porksen G., Naumann R., Geissler G., Thiede C., et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999, 67(February (4)):499-504.
11. Kiehl M.G., Schafer-Eckart K., Kroger M., Bornhauser M., Basara N., Blau I.W., et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002, 34(November (7)):2922-2924.
12. Bolwell B., Sobecks R., Pohlman B., Andresen S., Rybicki L., Kuczkowski E., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34(October (7)):621-625.
13. Neumann F., Graef T., Tapprich C., Vaupel M., Steidl U., Germing U., et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005, 35(June (11)):1089-1093.
14. Pohlreich D., Vitek A., Maalouf J., Cetkovsky P. Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens. Bone Marrow Transplant 2006, 37(January (2)):235-236. author reply 236-7.
15. Perkins J., Field T., Kim J., Kharfan-Dabaja M.A., Fernandez H., Ayala E., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16(July (7)):937-947.
16. Pinana J.L., Valcarcel D., Fernandez-Aviles F., Martino R., Rovira M., Barba P., et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010, 45(September (9)):1449-1456.
17. Busemann C., Wilfert H., Neumann T., Kiefer T., Dolken G., Kruger W.H. Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation. Onkologie 2011, 34(10):518-524.
18. Chen H., Liu K.Y., Liu D.H., Xu L.P., Han W., Chen Y.H., et al. Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases. Zhonghua Yi Xue Za Zhi 2008, 88(August (30)):2127-2130.
19. Doney K., Gooley T.A., Deeg H.J., Flowers M.E., Storb R., Appelbaum F.R. Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. Biol Blood Marrow Transplant 2011, 17(August (8)):1187-1195.
20. Koh L.P., Chen C.S., Tai B.C., Hwang W.Y., Tan L.K., Ng H.Y., et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biol Blood Marrow Transplant 2007, 13(July (7)):790-805.
21. Mielcarek M., Martin P.J., Leisenring W., Flowers M.E., Maloney D.G., Sandmaier B.M., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102(July (2)):756-762.
22. Ostronoff F., Ostronoff M., Souto-Maior A.P., Domingues M., Sucupira A., Manso D.A., et al. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant 2009, 23(January-February (1)):33-38.
23. Santarone S., Pidala J., Di Nicola M., Field T., Alsina M., Ayala E., et al. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transplant 2011, 17(October (10)):1505-1511.
24. Schetelig J., Kroger N., Held T.K., Thiede C., Krusch A., Zabelina T., et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002, 87(March (3)):299-305.
25. Snyder D.S., Palmer J., Gaal K., Stein A.S., Pullarkat V., Sahebi F., et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant 2010, 16(February (2)):281-286.
26. Valcarcel D., Martino R., Caballero D., Martin J., Ferra C., Nieto J.B., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008, 26(February (4)):577-584.
27. Dean R., Rybicki L., Sobecks R., Copelan E., Kalaycio M., Andresen S., et al. Comparison of cyclosporine and methotrexate with cyclosporine and mycophenolate mofetil for Gvhd prophylaxis in myeloablative allogeneic bone marrow transplantation. ASH annual meeting abstracts 2008, 2240.
28. Kiehl M.G., Armstrong V.W., Basara N., Blau I.W., Oellerich M., Fauser A.A. Intravenous mycophenolate mofetil plus prednisolone and cyclosporine in the prophylaxis of GVHD after stem cell transplantation. ASH annual meeting abstracts 1999, 671.
29. Kiehl M.G., Linck D., Schafer-Eckart K., Kroger M., Bornhauser M., Blau I.W., et al. Mycophenolate mofetil in combination with cyclosporine a (CSA)+-prednisolone versus CSA methotrexate+-prednisolone for the prophylaxis of acute GVHD after allogeneic stem cell transplantation. ASH annual meeting abstracts 2002, 2650.
30. Shimoni A., Rand A., Shem-Tov N., Hardan I., Volchek Y., Yerushalmi R., et al. Cyclosporine and methotrexate compared with cyclosporine and mycophenolate mofetil as GVHD prevention regimens in allogeneic stem-cell transplantation from unrelated donors; relative outcomes are dependant on disease status at transplantation. ASH annual meeting abstracts 2010, 2314.
31. Srinivasan R., Geller N., Chakrabarti S., Espinoza-Delgado I., Donohue T., Leitman S., et al. Evaluation of three different cyclosporine-based graft versus host disease (GVHD) prophylaxis regimens following nonmyeloablative hematopoietic stem cell transplantation (NST). ASH annual meeting abstracts 2004, 1236.
32. Minagawa K., Yamamori M., Katayama Y., Matsui T. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. Int J Hematol 2012, 96(July (1)):10-25.
33. Maris M.B., Sandmaier B.M., Storer B.E., Maloney D.G., Shizuru J.A., Agura E., et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006, 12(April (4)):454-465.
34. Nishikawa S., Okamura A., Yamamori M., Minagawa K., Kawamori Y., Kawano Y., et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transplant Proc 2009, 41(November (9)):3873-3876.
35. Wingard J., Nash R., Ratanatharathorn V., Fay J., Klein J., Przepiorka J., et al. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. Bone Marrow Transplant 1997, 20(July (1)):49-51.
36. Kuypers D. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008, 13(3):11-18.
37. Allison A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000, 47(May (2-3)):63-83.
38. Kharfan-Dabaja M., Mhaskar R., Pidala J.A., Perkins J.B., Djulbegovic B., Kumar A. Comparison of mycophenolate mofetil (MMF) versus methotrexate (MTX) for the prevention of graft-versus-host disease: results of a meta-analysis. CIBMTR tandem meeting 2012, 418.
39. Cutler C., Li S., Kim H.T., Laglenne P., Szeto K.C., Hoffmeister L., et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005, 11(May (5)):383-388.